Impact of Nitrate Ingestion on Protein Synthesis (PRO-Nitrate)
|ClinicalTrials.gov Identifier: NCT01473576|
Recruitment Status : Completed
First Posted : November 17, 2011
Last Update Posted : April 15, 2016
|Condition or disease||Intervention/treatment|
|Muscle Protein Synthesis||Dietary Supplement: Nitrate Dietary Supplement: Sodium chloride|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Impact of Dietary Nitrate Ingestion on Muscle Protein Synthesis in Elderly Type II Diabetics|
|Study Start Date :||August 2011|
|Primary Completion Date :||July 2012|
|Study Completion Date :||December 2013|
Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
Dietary Supplement: Nitrate
0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
Placebo Comparator: Sodium chloride
Sodium chloride placebo group
Dietary Supplement: Sodium chloride
0.15 mmol sodium chloride dissolved in 250 mL water.
- Muscle protein fractional synthetic rate [ Time Frame: -2, 0, +2, +5 h during the trial ]Muscle protein fractional synthetic rate assessed using the muscle biopsy technique.
- Plasma amino acids [ Time Frame: every 30 min (from -2 h to + 5 h during the test day) ]Blood sampling will occur through a catheter placed in an anticubital vein every 30 minutes throughout the test day. We will be using this plasma to measure plasma amino acids to determine the enrichment of labeled amino acids from both the IV tracer and the intrinsically-labeled casein protein. We wish to track the changes in amino acids from the intrinsically-labeled casein protein.
- Plasma nitrate [ Time Frame: every 30 min (from -2 h to + 5 h during the test day) ]Plasma nitrate will be measured every 30 minutes during the test day through blood sampling from the catheter inserted into an antecubital vein. We want to measure the changes in plasma nitrate after consuming the nitrate or placebo beverage.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01473576
|Maastricht, Limburg, Netherlands, 6229ER|
|Study Director:||Luc van Loon, PhD||Maastricht University|